SCHEMBL4139840

SCHEMBL4139840

[O-][n+]1cccc2c1c(-c1cccc(F)c1)nn2C(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.38
KDM4E B2RXH2 2/20 0.38
HTT P42858 2/20 0.38
XBP1 P17861 1/20 0.38
MAPK1 P28482 1/20 0.38
PTGER1 P34995 1/20 0.36
ADORA2A P29274 2/20 0.36
PTGS2 P35354 2/20 0.33
PTGS1 P23219 1/20 0.33
TP53 P04637 2/20 0.32
ADORA1 P30542 3/20 0.32
ADORA2B P29275 2/20 0.32
LMNA P02545 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
DPP4 P27487 1/20 0.32
CSNK1E P49674 1/20 0.31
MAPK13 O15264 1/20 0.31
RAF1 P04049 1/20 0.31
MAPK12 P53778 1/20 0.31
MAPK11 Q15759 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2471997 0.87 GRM2 (0.34) ALDH1A1KDM4EHTTPTGER1ADORA2A
SCHEMBL4137424 0.83 SRC (0.38) ADORA2AADORA1MAPK11MAPK14
SCHEMBL4141340 0.79 NFE2L2 (0.42) ALDH1A1KDM4EPTGS2PTGS1MAPT
SCHEMBL4141338 0.79 NFE2L2 (0.42) ALDH1A1KDM4EPTGS2PTGS1MAPT
SCHEMBL4148986 0.79 PTGER1 (0.37) ALDH1A1KDM4EHTTXBP1MAPK1
SCHEMBL4140254 0.75 PDE4A (0.39) ALDH1A1KDM4EHTTXBP1MAPK1
SCHEMBL4145541 0.74 HSP90AA1 (0.32) HTTMAPT
SCHEMBL5476722 0.74 GLS (0.31)
SCHEMBL2867613 0.74 ADORA2A (0.39) ALDH1A1KDM4EHTTXBP1MAPK1
SCHEMBL4136387 0.72 CSNK2A2 (0.41) ALDH1A1KDM4EHTTXBP1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090054397-A1 PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND OHI NORIHITO 2009-02-26 US disclosed
US-7429609-B2 Pyrazole compound and medicinal composition containing the same EISAI R & D MANAGEMENT CO., LTD. (JP) 2008-09-30 US disclosed
US-20050261339-A1 Pyrazole compound and medicinal composition containing the same EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-11-24 US disclosed
US-20050208582-A1 Pyrazole compounds and pharmaceutical compositions comprising the compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-09-22 US disclosed
EP-1510516-A1 PYRAZOLE COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME Eisai Co., Ltd. (JP) 2005-03-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054397-A1 PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND CNKSR1, NR3C2, CSNK2B ALDH1A1 2731/4885KDM4E 2622/4885HTT 3425/4885
US-20050261339-A1 Pyrazole compound and medicinal composition containing the same CNKSR1, NR3C2, CSNK2B ALDH1A1 2713/4885KDM4E 2795/4885HTT 3942/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.